Cat. No.: HY-134653

5-Ph-IAA

57 Cited Publications

Avis client

Based on 57 publication(s) in Google Scholar

5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.80%
CAS No.: 168649-23-8
Formule: C₁₆H₁₃NO₂
Masse moléculaire:251.28

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

5-Ph-IAA Chemical Structure

CAS No.: 168649-23-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (57)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain :

In Vitro

5-Ph-IAA (1 μM; 6 hours) leads to DHC1-mAC degradation in HCT116 cells constitutively expressing OsTIR1(F74G), which means the AID2 system better than the original AID system in generating conditional mutant cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

1 µM
Incubation Time:

6 hours
Result:

Depleted DHC1-mAC efficiently in HCT116 cells constitutively expressing OsTIR1(F74G).

In Vivo

5-Ph-IAA (0-10 mg/kg; intraperitoneally injection; every day; 7 days), used for the AID2 system, is sufficient to deplete mAID-BRD4 and TOP2A-mAC, leading to tumour suppression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells^[1]
Dosage:

0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:

Intraperitoneally injection; every day; 7 days
Result:

Displayed significant tumour suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts.

Chemical Information

CAS No. 168649-23-8
Appearance Solid
Masse moléculaire 251.28
Formule C₁₆H₁₃NO₂
Color White to light yellow
SMILES

O=C(O)CC1=CNC2=C1C=C(C3=CC=CC=C3)C=C2
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (57)

All WBCell Imaging/Staining

Sort by:

Journal Impact Factor

Nature

Mitotic bookmarking by SWI/SNF subunits. [Abstract]

2023 Jun;618(7963):180-187. PMID: 37225980

5-Ph-IAA purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7963):180-187. [Abstract]

Representative immunoblot in Smarce1-AID clones #6, #23, and #13het treated with 1 μM 5-Ph-IAA (0,10,30 min, 1,2,4, 6 h) for the indicated time following release from mitotic arrest. GAPDH was used as a loading control

5-Ph-IAA purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7963):180-187. [Abstract]

Representative immunoblot in mitotic Smarce1-AID cells (clones #6 and #23) treated with DMSO or 1 μM 5-Ph-IAA for 1 hour (lanes 1 and 2) and in cells that underwent washout and release from mitotic arrest for the indicated time periods.

5-Ph-IAA purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7963):180-187. [Abstract]

Cell morphologies of DMSO treated Smarce1-AID cells (clones #6 and #23) and the cells treated with 1 μM 5-Ph-IAA for the indicated days (0, 1, 3, 7 days).

5-Ph-IAA purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7963):180-187. [Abstract]

Representative immunoblot of Smarce1-AID cells (clones #6 and #23) treated with DMSO or 1 μM (30, 60, 240, 480 min, 1, 3, 7 days) 5-Ph-IAA.
Science

In silico protein interaction screening uncovers DONSON's role in replication initiation. [Abstract]

2023 Sep 22;381(6664):eadi3448. PMID: 37590370
Nat Immunol

Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development. [Abstract]

2024 Sep;25(9):1663-1677. PMID: 39179932
Nat Commun

Removal of promoter CpG methylation by epigenome editing reverses HBG silencing. [Abstract]

2025 Jul 27;16(1):6919. PMID: 40715076
Nat Commun

Systematic comparison and base-editing-mediated directed protein evolution and functional screening yield superior auxin-inducible degron technology. [Abstract]

2025 Jul 18;16(1):6631. PMID: 40681502
Nat Commun

m6A/IGF2BP3-driven serine biosynthesis fuels AML stemness and metabolic vulnerability. [Abstract]

2025 May 6;16(1):4214. PMID: 40328743
Mol Cell

Ribo-Tweezer: Rapid removal of ribosomal proteins reveals additional layers of post-transcriptional gene regulation. [Abstract]

2026 May 21:S1097-2765(26)00277-7. PMID: 42167236
Mol Cell

Transcription and cohesin direct domain boundary spatial positioning and are linked to Friedreich's ataxia. [Abstract]

2026 May 21;86(10):1911-1930.e11. PMID: 42127908
Mol Cell

Zinc-finger protein Zpr1 is a bespoke chaperone essential for eEF1A biogenesis. [Abstract]

2023 Jan 19;83(2):252-265.e13. PMID: 36630955

5-Ph-IAA purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Jan 19;83(2):252-265.e13. [Abstract]

5-Ph-IAA (5 μM; 1 h) rapidly induces Zpr1 depletion (Fig A), leading to cell growth arrest (Fig B), in ZPR1-AID cells.
Sci Adv

Chromatin conformation, gene transcription, and nucleosome remodeling as an emergent system. [Abstract]

2025 Jan 10;11(2):eadq6652. PMID: 39792661
Sci Adv

Mature chromatin packing domains persist after RAD21 depletion in 3D. [Abstract]

2025 Jan 24;11(4):eadp0855. PMID: 39854464
Nat Struct Mol Biol

Topoisomerase-modulated genome-wide DNA supercoiling domains colocalize with nuclear compartments and regulate human gene expression. [Abstract]

2025 Jan;32(1):48-61. PMID: 39152238
Genome Biol

Deciphering the role of RNA in regulating CTCF's DNA binding affinity in leukemia cells. [Abstract]

2025 May 12;26(1):126. PMID: 40355969
Genome Biol

Auxin-inducible degron 2 system deciphers functions of CTCF domains in transcriptional regulation. [Abstract]

2023 Jan 26;24(1):14. PMID: 36698211
Cell Genom

Long-range enhancer-controlled genes are hypersensitive to regulatory factor perturbations. [Abstract]

2025 Mar 12;5(3):100778. PMID: 40010352
J Genet Genomics

Dissecting the functional roles of CTCF and CTCF-s in human embryonic stem cells. [Abstract]

2025 Dec 23:S1673-8527(25)00349-2. PMID: 41448493
Cell Rep

2026 Apr 28;45(4).
Cell Rep

RNA polymerase II drives FUS and EWSR1 exclusion from damaged chromatin. [Abstract]

2026 Apr 8;45(4):117236. PMID: 41955098
Curr Biol

Polarized SOS activity orchestrates FGF-directed cell migration in vivo. [Abstract]

2026 Apr 20;36(8):1977-1993.e8. PMID: 41923633
Genes Dev

Two unrelated distal genes activated by a shared enhancer benefit from localizing inside the same small topological domain. [Abstract]

2025 Mar 3;39(5-6):348-363. PMID: 39870429
PLoS Biol

Detailed characterisation of the trypanosome nuclear pore architecture reveals conserved asymmetrical functional hubs that drive mRNA export. [Abstract]

2025 Feb 3;23(2):e3003024. PMID: 39899609
Genetics

Genetic Analysis of JNK MAPK Signaling in Stress-Induced Avoidance Behavior in C. elegans. [Abstract]

2025 Jul 28:iyaf143. PMID: 40719140
Commun Biol

Revealing acute consequences of rapid degradation of synaptic fusion proteins at individual synapses using Auxin-Inducible Degron 2 technology. [Abstract]

2025 Nov 17;8(1):1589. PMID: 41249467
PLoS One

Trypanosomes lack a canonical EJC but possess an UPF1 dependent NMD-like pathway. [Abstract]

2025 Mar 7;20(3):e0315659. PMID: 40053537
bioRxiv

TREX2 component PCID2 scaffolds alternative SAC3-based subcomplexes with distinct RNA processing and export function. [Abstract]

2026 Apr 14:2026.04.13.716336. PMID: 42039562
bioRxiv

2026 Mar 26.
bioRxiv

Gene transcription and chromatin packing domains form a self- organizing system. [Abstract]

2026 Mar 17:2026.03.15.711889. PMID: 41889979
Northwestern University

2026.
bioRxiv

Chromatin modifiers KMT2D, BAF, and p300 are required for de novo binding of transcription factors on enhancers. [Abstract]

2026 Jan 29:2026.01.29.702555. PMID: 41659470
bioRxiv

2026 Jan 29.
bioRxiv

2025 Dec 23.
University of Wurzburg

2025.
Heidelberg University

2026 Jan 2.
bioRxiv

2025 Nov 19.
bioRxiv

2025 Nov 5.
bioRxiv

2025 Oct 23.
bioRxiv

2025 Sep 9.
University of Rochester

2025.
University of Pennsylvania

2025.
bioRxiv

Deciphering acquired resistance mechanisms to sustained auxin-inducible protein degradation in cells and mice. [Abstract]

2025 Sep 23:2025.09.21.677607. PMID: 41040178
Dartmouth College

2025.
bioRxiv

The nucleus forms a dynamic contact with the plasma membrane to maintain the glandular epithelial architecture. [Abstract]

2025 Jun 15:2025.06.13.659552. PMID: 40661617
bioRxiv

2025 May 23.
bioRxiv

2025 April 02.
bioRxiv

2025 March 24.
bioRxiv

Polo-like kinase 1 maintains transcription and chromosomal accessibility during mitosis. [Abstract]

2025 Feb 16:2025.02.12.637959. PMID: 39990329
bioRxiv

An auxin-inducible degron system for conditional mutation in the fungal meningitis pathogen Cryptococcus neoformans. [Abstract]

2024 Nov 18:2024.11.18.624150. PMID: 39605730
bioRxiv

2024 Oct 03.
bioRxiv

2024 October 22.
bioRxiv

2024 October 26.
Res Sq

Comparative analysis and directed protein evolution yield an improved degron technology with minimal basal degradation, rapid inducible depletion, and faster recovery of target proteins. [Abstract]

2024 Nov 15:rs.3.rs-5348956. PMID: 39606491
bioRxiv

2024 September 10.
bioRxiv

2024 Mar 28.
bioRxiv

Transcriptome-wide mRNA condensation precedes stress granule formation and excludes stress-induced transcripts. [Abstract]

2024 May 2:2024.04.15.589678. PMID: 38659805
bioRxiv

2024 Jan 25.
Dartmouth College

2023 Jul 17
bioRxiv

2023 Aug 19.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (397.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9796 mL

19.8981 mL

39.7962 mL

5 mM

0.7959 mL

3.9796 mL

7.9592 mL

10 mM

0.3980 mL

1.9898 mL

3.9796 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1 mg/mL (3.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Aisha Yesbolatova, et al. The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice. Nat Commun. 2020 Nov 11;11(1):5701. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9796 mL	19.8981 mL	39.7962 mL	99.4906 mL
	5 mM	0.7959 mL	3.9796 mL	7.9592 mL	19.8981 mL
	10 mM	0.3980 mL	1.9898 mL	3.9796 mL	9.9491 mL
	15 mM	0.2653 mL	1.3265 mL	2.6531 mL	6.6327 mL
	20 mM	0.1990 mL	0.9949 mL	1.9898 mL	4.9745 mL
	25 mM	0.1592 mL	0.7959 mL	1.5918 mL	3.9796 mL
	30 mM	0.1327 mL	0.6633 mL	1.3265 mL	3.3164 mL
	40 mM	0.0995 mL	0.4975 mL	0.9949 mL	2.4873 mL
	50 mM	0.0796 mL	0.3980 mL	0.7959 mL	1.9898 mL
	60 mM	0.0663 mL	0.3316 mL	0.6633 mL	1.6582 mL
	80 mM	0.0497 mL	0.2487 mL	0.4975 mL	1.2436 mL
	100 mM	0.0398 mL	0.1990 mL	0.3980 mL	0.9949 mL

Keywords

5-Ph-IAA

57 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

5-Ph-IAA

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 5-Ph-IAA

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain

Activité biologique

Chemical Information

Publications (57)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

5-Ph-IAA

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) 5-Ph-IAA

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain

Activité biologique

Chemical Information

Publications (57)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

5-Ph-IAA Related Classifications

HY-134653 Related Classifications